Companies in #Primary Ciliary Dyskinesia

ReCode Therapeutics is a clinical-stage genetic medicines company using its proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene correction therapeutics directly to the lungs and other organs beyond the liver. Its lead programs target cystic fibrosis and primary ciliary dyskinesia, rare genetically defined diseases with no existing treatment options.